Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-25365
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrobet, Cécile-
dc.contributor.authorAudigé, Laurent-
dc.contributor.authorEichler, Klaus-
dc.contributor.authorMeier, Flurina-
dc.contributor.authorMarks, Miriam-
dc.contributor.authorHerren, Daniel B.-
dc.date.accessioned2022-07-27T09:25:03Z-
dc.date.available2022-07-27T09:25:03Z-
dc.date.issued2022-
dc.identifier.issn0363-5023de_CH
dc.identifier.issn1531-6564de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/25365-
dc.description.abstractPurpose: Knowledge about the costs and benefits of hand surgical interventions is important for surgeons, payers, and policy makers. Little is known about the cost-effectiveness of surgery for thumb carpometacarpal osteoarthritis. The objective of this study was to examine patients’ quality of life and economic costs, with focus on the cost-utility ratio 1 year after surgery for thumb carpometacarpal osteoarthritis compared with that for continued nonsurgical management. Methods: Patients with thumb carpometacarpal osteoarthritis indicated for resection arthroplasty were included in a prospective study. The quality of life (using European Quality of Life-5 Dimensions-5 Level), direct medical costs, and productivity losses were assessed up to 1 year after surgery. Baseline data at recruitment and costs sustained over 1 year before surgery served as a proxy for nonsurgical management. The total costs to gain 1 extra quality-adjusted life year and the incremental cost-effectiveness ratio were calculated from a health care system and a societal perspective. Results: The mean European Quality of Life-5 Dimensions-5 Level value for 151 included patients improved significantly from 0.69 to 0.88 (after surgery). The productivity loss during the preoperative period was 47% for 49 working patients, which decreased to 26% 1 year after surgery. The total costs increased from US $20,451 in the preoperative year to US $24,374 in the postoperative year. This resulted in an incremental cost-effectiveness ratio of US $25,370 per quality-adjusted life year for surgery compared with that for simulated nonsurgical management. Conclusions: The calculated incremental cost-effectiveness ratio was clearly below the suggested Swiss threshold of US $92,000, indicating that thumb carpometacarpal surgery is a cost-effective intervention.de_CH
dc.language.isoende_CH
dc.publisherElsevierde_CH
dc.relation.ispartofJournal of Hand Surgery (American Volume)de_CH
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/de_CH
dc.subjectCost-effectivenessde_CH
dc.subjectCost-utilityde_CH
dc.subjectQuality of lifede_CH
dc.subjectThumb carpometacarpal osteoarthritisde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.subject.ddc617.5: Orthopädische Chirurgiede_CH
dc.titleCost-utility analysis of thumb carpometacarpal resection arthroplasty : a health economic study using real-world datade_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
dc.identifier.doi10.1016/j.jhsa.2022.01.013de_CH
dc.identifier.doi10.21256/zhaw-25365-
dc.identifier.pmid35346526de_CH
zhaw.funding.euNode_CH
zhaw.issue5de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end453de_CH
zhaw.pages.start445de_CH
zhaw.publication.statusacceptedVersionde_CH
zhaw.volume47de_CH
zhaw.embargo.end2023-05-01de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
File Description SizeFormat 
2022_Grobet-etal_Cost-utility-analysis-thumb-carpometacarpal.pdf
  Until 2023-05-01
525.28 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.